Psychosocial and Cultural Determinants of Interest and Uptake of Skin Cancer Genetic Testing in Diverse Primary Care.
Adult
Attitude to Health
Cultural Diversity
Female
Genetic Testing
/ methods
Health Literacy
Hispanic or Latino
/ psychology
Humans
Male
Melanoma
/ ethnology
Middle Aged
New Mexico
/ epidemiology
Primary Health Care
/ methods
Psychology
Receptor, Melanocortin, Type 1
/ analysis
Skin Neoplasms
/ ethnology
Culture
Hispanics
Primary care
Psychosocial factors
Skin cancer risk
Journal
Public health genomics
ISSN: 1662-8063
Titre abrégé: Public Health Genomics
Pays: Switzerland
ID NLM: 101474167
Informations de publication
Date de publication:
2019
2019
Historique:
received:
05
12
2018
accepted:
07
07
2019
pubmed:
23
8
2019
medline:
7
1
2020
entrez:
23
8
2019
Statut:
ppublish
Résumé
Translational research in genomics has limited reach and requires efforts to broaden access and utility in diverse populations. Skin cancer is common and rates are rising, including among Hispanics. Germline variants in the melanocortin-1 receptor (MC1R) gene are common in the population and confer moderate risk for melanoma and basal cell cancers across skin types. Feedback about MC1R risk status may promote skin cancer risk awareness and risk reduction. We examined the level of interest in pursuing MC1R testing, and patterns of interest across skin cancer perceived threat and control attitudes, cultural beliefs (family influence on health, health system distrust, cancer fatalism, skin cancer misconceptions), and health literacy. We used a study website to inform primary care patients in Albuquerque, NM about the benefits and drawbacks of MC1R testing. Website logon, request of a saliva test kit, and return of the test kit (yes vs. no) were primary assessments of study interest and uptake. Of 499 participants provided with a test offer, 33% requested and returned the test. Lower family influence on participants' health was an important factor both overall and within ethnicity subgroups, and may indicate that primary care patients interested in skin cancer genetic testing see themselves as proactive health seekers, independent from family encouragement. Lower self-efficacy for skin cancer prevention was also an important characteristic of those who tested. As evidence for common genetic markers for skin cancer accumulates, these findings suggest characteristics of those most likely to pursue genetic testing for skin cancer risk.
Sections du résumé
BACKGROUND
Translational research in genomics has limited reach and requires efforts to broaden access and utility in diverse populations. Skin cancer is common and rates are rising, including among Hispanics. Germline variants in the melanocortin-1 receptor (MC1R) gene are common in the population and confer moderate risk for melanoma and basal cell cancers across skin types. Feedback about MC1R risk status may promote skin cancer risk awareness and risk reduction.
AIMS
We examined the level of interest in pursuing MC1R testing, and patterns of interest across skin cancer perceived threat and control attitudes, cultural beliefs (family influence on health, health system distrust, cancer fatalism, skin cancer misconceptions), and health literacy.
METHODS
We used a study website to inform primary care patients in Albuquerque, NM about the benefits and drawbacks of MC1R testing. Website logon, request of a saliva test kit, and return of the test kit (yes vs. no) were primary assessments of study interest and uptake.
RESULTS
Of 499 participants provided with a test offer, 33% requested and returned the test. Lower family influence on participants' health was an important factor both overall and within ethnicity subgroups, and may indicate that primary care patients interested in skin cancer genetic testing see themselves as proactive health seekers, independent from family encouragement. Lower self-efficacy for skin cancer prevention was also an important characteristic of those who tested.
CONCLUSION
As evidence for common genetic markers for skin cancer accumulates, these findings suggest characteristics of those most likely to pursue genetic testing for skin cancer risk.
Identifiants
pubmed: 31437847
pii: 000501985
doi: 10.1159/000501985
pmc: PMC7814986
mid: NIHMS1621392
doi:
Substances chimiques
Receptor, Melanocortin, Type 1
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
58-68Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA118100
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA181241
Pays : United States
Informations de copyright
© 2019 S. Karger AG, Basel.
Références
Am J Health Promot. 2012 Jan-Feb;26(3):176-9
pubmed: 22208416
Genet Med. 2009 Sep;11(9):655-62
pubmed: 19752639
Cancer Epidemiol Biomarkers Prev. 2017 Feb;26(2):212-221
pubmed: 27702805
Pigment Cell Melanoma Res. 2010 Oct;23(5):587-606
pubmed: 20546537
Fam Med. 2004 Sep;36(8):588-94
pubmed: 15343421
Arch Dermatol. 1988 Jun;124(6):869-71
pubmed: 3377516
Am J Prev Med. 2009 Dec;37(6):524-30
pubmed: 19944919
Health Psychol. 2018 Dec;37(12):1134-1144
pubmed: 30307272
Psychooncology. 2011 Mar;20(3):313-20
pubmed: 20878831
JMIR Res Protoc. 2017 Apr 25;6(4):e52
pubmed: 28442450
Cancer. 2011 Jan 1;117(1):152-61
pubmed: 20737564
Med Care. 2012 May;50(5):381-7
pubmed: 22473221
Cancer Prev Res (Phila). 2018 Mar;11(3):121-124
pubmed: 29246956
J Genet Couns. 2011 Dec;20(6):625-38
pubmed: 21691939
J Health Commun. 2004 Sep-Oct;9(5):443-60; discussion 81-4
pubmed: 15513791
Public Health Genomics. 2012;15(2):57-72
pubmed: 21921576
Int J Behav Med. 2011 Dec;18(4):310-8
pubmed: 20953916
Int J Cancer. 2008 Jun 15;122(12):2753-60
pubmed: 18366057
J Health Commun. 2002 Jul-Sep;7(4):325-40
pubmed: 12356290
J Cancer Educ. 2017 Sep;32(3):438-446
pubmed: 26687207
Cancer. 2010 May 15;116(10):2416-28
pubmed: 20301115
J Gen Intern Med. 2008 May;23(5):561-6
pubmed: 18335281
Health Psychol. 2015 Feb;34(2):101-10
pubmed: 25622080
Public Health Genomics. 2011;14(2):85-93
pubmed: 20299772
Cancer. 2006 Mar 1;106(5):1162-8
pubmed: 16429450
Arch Dermatol. 2006 Jun;142(6):704-8
pubmed: 16785372
Arch Dermatol. 2009 Dec;145(12):1369-74
pubmed: 20026844
J Invest Dermatol. 2018 Dec;138(12):2617-2624
pubmed: 29890168
J Health Commun. 1996 Oct-Dec;1(4):317-41
pubmed: 10947367
J Behav Med. 1982 Dec;5(4):441-60
pubmed: 7154065
Genet Med. 2010 Sep;12(9):556-66
pubmed: 20717041
Med Decis Making. 2013 Feb;33(2):271-81
pubmed: 23468476
Arch Dermatol. 2010 Jul;146(7):741-6
pubmed: 20644034
Int J Cancer. 2015 Feb 1;136(3):618-31
pubmed: 24917043
JAMA Dermatol. 2018 Jun 1;154(6):684-693
pubmed: 29801061
Genome Med. 2012 Nov 29;4(11):92
pubmed: 23194586
Oncol Nurs Forum. 1995 Oct;22(9):1355-9
pubmed: 8539176
Public Health Genomics. 2011;14(6):356-70
pubmed: 21540561
J Gen Intern Med. 2008 Jun;23(6):727-32
pubmed: 18369678
Per Med. 2016 Jan;13(1):1-4
pubmed: 29749865
N Engl J Med. 2011 Feb 10;364(6):524-34
pubmed: 21226570
J Am Acad Dermatol. 2002 Jul;47(1):118-23
pubmed: 12077590
Genet Med. 2017 Aug;19(8):858-863
pubmed: 28079898
Genet Med. 2010 Feb;12(2):105-15
pubmed: 20061960
J Community Genet. 2017 Jan;8(1):53-63
pubmed: 27924449
Health Informatics J. 2008 Mar;14(1):29-38
pubmed: 18258673
J Cancer Educ. 1994 Summer;9(2):105-10
pubmed: 7917894
Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1212-6
pubmed: 16775183
Cancer Epidemiol Biomarkers Prev. 2012 Oct;21(10):1701-8
pubmed: 23045545
J Health Commun. 2013;18(1):58-70
pubmed: 23066874
J Genet Couns. 2010 Dec;19(6):618-29
pubmed: 20798982
JAMA Dermatol. 2013 Jan;149(1):103-4
pubmed: 23324772
Br J Cancer. 2015 Jul 14;113(2):354-63
pubmed: 26103569
J Med Syst. 2006 Aug;30(4):241-9
pubmed: 16978003
J Behav Med. 2014 Dec;37(6):1082-90
pubmed: 24532153
Health Educ Behav. 2009 Oct;36(5 Suppl):91S-110S
pubmed: 19805793
Health Psychol. 2018 Jun;37(6):553-561
pubmed: 29745680